1. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer. Issue 1 (2nd January 2023) Authors: Yang, James Chih-Hsin; Zhou, Caicun; Jänne, Pasi A.; Ramalingam, Suresh S.; Kim, Tae Min; Riely, Gregory J; Spira, Alexander I; Piotrowska, Zofia; Mekhail, Tarek; Garcia Campelo, Maria Rosario; Felip, Enriqueta; Bazhenova, Lyudmila; Jin, Shu; Kaur, Manmit; Diderichsen, Paul M.; Gupta, Neeraj; Bun... Journal: Expert review of anticancer therapy Issue: Volume 23:Issue 1(2023) Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison. (May 2023) Authors: Ou, Sai-Hong I.; Lin, Huamao M.; Hong, Jin-Liern; Yin, Yu; Jin, Shu; Lin, Jianchang; Mehta, Minal; Zhang, Pingkuan; Nguyen, Danny; Neal, Joel W. Journal: Lung cancer Issue: Volume 179(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study. (March 2022) Authors: Popat, Sanjay; Ramalingam, Suresh; Kim, Tae Min; Yang, James; Riely, Gregory; Mekhail, Tarek; Nguyen, Danny; Garcia Campelo, Maria Rosario; Felip, Enriqueta; Spira, Alexander; Piotrowska, Zofia; Bazhenova, Lyudmila; Vincent, Sylvie; Jin, Shu; Griffin, Celina; Diderichsen, Paul; Gupta, Neeraj; Bun... Journal: Lung cancer Issue: Volume 165(2022)Supplement 1 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study. Issue 2 (29th May 2022) Authors: Gupta, Neeraj; Largajolli, Anna; Witjes, Han; Diderichsen, Paul M.; Zhang, Steven; Hanley, Michael J.; Lin, Jianchang; Mehta, Minal Journal: Clinical pharmacology & therapeutics Issue: Volume 112:Issue 2(2022) Page Start: 327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗